U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
996 articles with Allergan, Inc.
Allergan Inc. Announces FDA Approval of LATISSE -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
FDA Advisory Committee Recommends Approval of Allergan Inc.'s First Prescription Eyelash Enhancer Latisse
Spectrum Pharmaceuticals, Inc. Announces Receipt of $41.5 Million from Allergan Inc. (JOBS) Per Collaboration Agreement for Apaziquone Announced on October 29th
Polyphor to Enter into an Exclusive Agreement with Allergan Inc. for the Development of Protein Epitope Mimetics (PEM) Inhibitors for Ophthalmology; Allergan Entitled to Receive up to $61.0 Million
Allergan Inc. And Spectrum Pharmaceuticals, Inc. Announce Collaboration Agreement for Apaziquone (EOquin(R)} for an Upfront Payment of $41.5M; Spectrum May Earn Up to $304 Million in Milestones and Retains Asian Rights
BAROnova Secures Series B Financing of $7.5M From Allergan Inc.; New Obesity Intervention Device Moving to New Clinical Trials Has the Potential to be Safer and More Cost Effective Without Surgery
Allergan Inc. Announces Positive Top-Line Results from Phase III BOTOX(R) Headache Program; Studies Show Statistically Significant Decrease in Number of Headache Days; Stock Rises
Asterand, Inc. to Enter Into Exclusive License Agreement with Allergan Inc. for Pre-Clinical Compounds Focused on Diseases of the Eye; Asterand to Receive Upfront Payment of $6.25M; Deal Could Produce of up to $56M in Milestone Payments, Plus Royalties
Validity of Allergan Inc. Patents Acknowledged by Jan Marini in Settlement of Allergan Inc.'s Patent Infringement Suit Against Jan Marini Skin Research, Inc.